LONDON, Jun 19, 2012 (BUSINESS WIRE) –
Cancer Research Technology (CRT), the cancer-focused technology
development and commercialization arm of Cancer Research UK, announced
today the implementation of the Labcyte Access workstation to automate
the production of assay-ready plates to be used in a high-throughput
cell based screening program.
The Access workstation incorporates the Labcyte Echo(R) liquid handler–a
revolutionary platform using acoustic liquid transfer–in a compact
robotic plate handling system to enable walk-away production of low
volume assay-ready plates. The Echo liquid handler does not require the
use of pipette tips, pin tools, or nozzles, which provides unsurpassed
precision and accuracy. By adding a range of device options and
accessories, the Access workstation can adapt to the evolving
requirements of applications in genomics, drug discovery and more.
The leading driver behind CRT’s purchase of the Access workstation was
an overall reduction in compound consumption. Reduced compound
consumption and assay volume allows CRT to increase their overall
productivity by screening compounds across more assays at a time. In
addition, automated acoustic liquid handling significantly improves data
with the elimination of artifacts from cross-contamination or user
errors.
“We already see the improved data quality for assays that have
transitioned to the Access workstation,” says Fabrice Turlais, group
leader HTS and compound management. “The improvements are seen in
routine compound profiling assays as well as improve reproducibility in
our cell-based HTS results. We can easily foresee the reduction in
resource required for routine preparation of cell based IC50 assays and
a significant improvement in the speed and flexibility of testing
different concentrations for dose-response.”
“Echo liquid handlers have already had a significant impact on drug
discovery efforts in the pharmaceutical industry,” says Mark
Fischer-Colbrie, CEO and president of Labcyte. “Our technology is now
poised to bring similar advances across a wide range of genomic and
cell-based applications. We are pleased to see CRT immediately realize
these benefits with their efforts in cancer research.”
About Cancer Research Technology
Cancer Research Technology (CRT) is a specialized commercialization and
development company, which aims to develop new discoveries in cancer
research for the benefit of cancer patients. CRT works closely with
leading international cancer scientists and their institutes to protect
intellectual property arising from their research and to establish links
with commercial partners. CRT facilitates the discovery, development and
marketing of new cancer therapeutics, vaccines, diagnostics and enabling
technologies. CRT is a wholly owned subsidiary of Cancer Research UK,
the world’s leading cancer charity dedicated to saving lives through
research. CRT’s discovery laboratories build on exploratory research to
create attractive commercial opportunities through collaboration with
research institutes worldwide. Therapeutic programs are then
out-licensed for further development following identification of a
suitable partner. Further information about CRT can be found at
www.cancertechnology.com .
About Labcyte
Labcyte, a global life science instrumentation company, is
revolutionizing liquid handling. Echo liquid handling systems use sound
to precisely transfer liquids. The environmentally-friendly Echo
platform generates better results with significantly lower costs when
compared to traditional liquid handling systems that have high running
costs, are prone to transfer errors, risk sample contamination and waste
large amounts of plastic lab consumables. Labcyte instruments are used
worldwide by all of the top ten pharmaceutical companies, as well as by
small to mid-size pharmaceutical companies, biotechnology firms,
contract research organizations and academic institutions. Our customers
work across a wide spectrum of biology including drug discovery,
genomics, proteomics, diagnostics, imaging mass spectrometry and live
cell transfer. Labcyte, headquartered in Sunnyvale, California, has
global sales and support. Labcyte has 46 U.S., 10 European, 5 Japanese
and 1 Chinese patents with additional U.S. and international filings.
For more information, visit
www.labcyte.com .
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50313256lang=en
SOURCE: Labcyte Inc.
Cancer Research Technology Dr. Fabrice Turlais Group Leader Tel: +44 (0)207 679 0973 Fax: +44 (0)207 679 6718 fturlais@cancertechnology.com www.cancertechnology.co.uk/ or Labcyte Inc. Pamela Lo Toll-free: 877-742-6548 Tel: 408-747-2000 x211 Fax: 408-747-2010 pamela.lo@labcyte.com www.labcyte.com
Copyright Business Wire 2012
No comments:
Post a Comment